Loading
NeoGenomics' personalised blood test for tiny amounts of leftover cancer, tracking up to 48 mutations from the patient's own tumour.
RaDaR was developed by Inivata (Cambridge, UK), acquired by NeoGenomics in 2021, and received FDA Breakthrough Device designation in 2021 for detecting residual disease and recurrence. Tracking dozens of variants at once lets it reach very low tumour fractions (parts per hundred thousand in validation studies) and it has been used in head and neck, breast and lung cancer cohorts, including the TRACERx-associated work in lung cancer. It is offered as a laboratory-developed test and competes with Signatera, Guardant Reveal and Oncodetect in a market that Medicare coverage decisions largely shape.
Whole-exome sequencing of the tumour selects up to 48 patient-specific variants, which are tracked in plasma by deep amplicon sequencing with error suppression.
1.RaDaR slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RaDaR" OR ABSTRACT:"RaDaR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RaDaR, not a curated reading list.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Signatera, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag test.
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Non-small-cell lung cancer and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag test.
Shares Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag test.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag test.